Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate
Lineage Cell Therapeutics Q1 EPS $(0.03) Vs. $(0.04) Prior Year, Sales $2.39M Beat $2.01M Estimate
Lineage Cell Therapeutics第一季度每股收益爲0.03美元,去年同期爲0.04美元,銷售額爲239萬美元,超過預期的201萬美元
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $2.39 million which beat the analyst consensus estimate of $2.01 million by 18.71 percent. This is a 54.44 percent decrease over sales of $5.24 million the same period last year.
Lineage Cell Therapeutics(AMEX: LCTX)公佈的季度每股虧損爲0.03美元。與去年同期相比,每股虧損0.04美元,增長了25%。該公司公佈的季度銷售額爲239萬美元,比分析師共識估計的201萬美元高出18.71%。這比去年同期的524萬美元銷售額下降了54.44%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。